ROCKWELL MEDICAL,INC. (NASDAQ:RMTI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

As previously reported in the Original Filing, at the 2017 Annual Meeting, the shareholders recommended, by non-binding vote, that the frequency of shareholder advisory votes on the compensation of the Company’s named executive officers be every year as follows:

In light of these results and such other factors as the Company’s Board of Directors (the “Board”) deemed relevant, the Board determined that the Company will hold an advisory vote on the compensation of the Company’s named executive officers on an annual basis until the next shareholder vote on the frequency of such advisory vote is conducted or until the Board determines that a different frequency for such advisory vote would be in the best interest of the Company’s shareholders.

About ROCKWELL MEDICAL,INC. (NASDAQ:RMTI)

Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its lead branded drug, Triferic is indicated for iron maintenance. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Its generic drug, Calcitriol, is indicated for treating secondary hyperparathyroidism in dialysis patients. It manufactures, sells, delivers and distributes hemodialysis concentrates, along with a range of ancillary products.